{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T07:18:44Z","timestamp":1763018324225,"version":"3.41.2"},"reference-count":111,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract:<\/jats:title>\n          <jats:p>Aldosterone, a mineralocorticoid hormone, plays a role in the pathophysiology of many cardiovascular disease states. Mineralocorticoid receptor antagonists (MRAs) have been shown to improve clinical outcomes in select patient populations. However, use of available steroidal receptor antagonists, eplerenone and spironolactone, is often limited by the risk or development of hyperkalemia. Nonsteroidal MRAs have been designed to overcome this limitation. The nonsteroidal MRAs have been studied in patients with heart failure with reduced ejection fraction, hypertension, and to lower the risk of cardiac and renal outcomes in those with type 2 diabetes and renal disease. In this review, the pharmacology of the MRAs is compared, the data evaluating the use of nonsteroidal MRAs are examined, and the place of this new generation of therapy is discussed. At this time, it seems that there could be a future role for nonsteroidal MRAs to reduce the risk of renal outcomes in high-risk individuals.<\/jats:p>","DOI":"10.1097\/fjc.0000000000000990","type":"journal-article","created":{"date-parts":[[2021,3,24]],"date-time":"2021-03-24T17:02:41Z","timestamp":1616605361000},"page":"685-698","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Nonsteroidal Mineralocorticoid Receptor Antagonists: Exploring Role in Cardiovascular Disease"],"prefix":"10.1097","volume":"77","author":[{"given":"Kristin","family":"Watson","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice and Science, University of Maryland School of Pharmacy, Baltimore, MD;"},{"name":"ATRIUM Cardiology Collaborative, Baltimore, MD;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alina","family":"Kukin","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Hospital of the University of Pennsylvania, Philadelphia, PA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allie K.","family":"Wasik","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Northwestern Memorial Hospital Bluhm Cardiovascular Institute, Chicago, IL; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine E.","family":"Shulenberger","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Penn State Health Milton S. Hershey Medical Center, Hershey, PA."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,6]]},"reference":[{"key":"R1-20250802","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College Of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"62","author":"Yancy","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"R2-20250802","first-page":"e13","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American college of cardiology\/American heart association task force on clinical practice guidelines","volume":"71","author":"Whelton","year":"2018","journal-title":"Hypertension"},{"key":"R3-20250802","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1056\/NEJMoa040135","article-title":"Rates of hyperkalemia after publication of the randomized Aldactone evaluation study","volume":"351","author":"Juurlink","year":"2004","journal-title":"N Engl J Med"},{"key":"R4-20250802","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.jacc.2005.06.010","article-title":"The adequacy of laboratory monitoring in patients treated with spironolactone for congestive heart failure","volume":"46","author":"Shah","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"R5-20250802","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"R6-20250802","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"R7-20250802","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.kint.2019.02.030","article-title":"Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis","volume":"96","author":"Barrera-Chimal","year":"2019","journal-title":"Kidney Int"},{"key":"R8-20250802","doi-asserted-by":"crossref","first-page":"1204598","DOI":"10.1155\/2018\/1204598","article-title":"Aldosterone and mineralocorticoid receptor system in cardiovascular physiology and pathophysiology","volume":"2018","author":"Cannavo","year":"2018","journal-title":"Oxid Med Cell Longev"},{"key":"R9-20250802","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1161\/CIRCHEARTFAILURE.109.868513","article-title":"Serum cortisol as a useful predictor of cardiac events in patients with chronic heart failure: the impact of oxidative stress","volume":"2","author":"Yamaji","year":"2009","journal-title":"Circ Heart Fail"},{"key":"R10-20250802","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.pcad.2009.12.003","article-title":"Aldosterone and mineralocorticoid receptors in the cardiovascular system","volume":"52","author":"Funder","year":"2010","journal-title":"Prog Cardiovasc Dis"},{"key":"R11-20250802","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1056\/NEJMra000050","article-title":"Aldosterone in congestive heart failure","volume":"345","author":"Weber","year":"2001","journal-title":"N Engl J Med"},{"key":"R13-20250802","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1056\/NEJM199407283310408","article-title":"Disorders of aldosterone biosynthesis and action","volume":"331","author":"White","year":"1994","journal-title":"N Engl J Med"},{"key":"R14-20250802","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2147\/VHRM.S13779","article-title":"Aldosterone and aldosterone receptor antagonists in patients with chronic heart failure","volume":"7","author":"Nappi","year":"2011","journal-title":"Vasc Health Risk Manag"},{"key":"R15-20250802","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1016\/j.bbamcr.2013.05.009","article-title":"Aldosterone regulates Na(+), K(+) ATPase activity in human renal proximal tubule cells through mineralocorticoid receptor","volume":"1833","author":"Salyer","year":"2013","journal-title":"Biochim Biophys Acta"},{"key":"R16-20250802","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1681\/ASN.V1271335","article-title":"Loop diuretic infusion increases thiazide-sensitive Na(+)\/Cl(-)-cotransporter abundance: role of aldosterone","volume":"12","author":"Abdallah","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"R17-20250802","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1172\/JCI10366","article-title":"The renal thiazide-sensitive Na-Cl cotransporter as mediator of the aldosterone-escape phenomenon","volume":"108","author":"Wang","year":"2001","journal-title":"J Clin Invest"},{"key":"R18-20250802","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.mce.2011.06.038","article-title":"Aldosterone, mineralocorticoid receptor, and heart failure","volume":"350","author":"Messaoudi","year":"2012","journal-title":"Mol Cell Endocrinol"},{"key":"R19-20250802","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/BF00877755","article-title":"\u201cEscape\u201d of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy","volume":"9","author":"Pitt","year":"1995","journal-title":"Cardiovasc Drugs Ther"},{"key":"R20-20250802","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1006\/jmcc.2000.1129","article-title":"Induction of cardiac fibrosis by aldosterone","volume":"32","author":"Lijnen","year":"2000","journal-title":"J Mol Cell Cardiol"},{"key":"R21-20250802","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1210\/jc.2003-030373","article-title":"Aldosterone: direct effects on and production by the heart","volume":"88","author":"White","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"R22-20250802","doi-asserted-by":"crossref","first-page":"313","DOI":"10.3389\/fphar.2017.00313","article-title":"Mineralocorticoid receptor signaling as a therapeutic target for renal and cardiac fibrosis","volume":"8","author":"Tesch","year":"2017","journal-title":"Front Pharmacol"},{"key":"R23-20250802","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0008-6363(00)00092-4","article-title":"Renin\u2013angiotensin\u2013aldosterone system and myocardial fibrosis","volume":"47","author":"Brilla","year":"2000","journal-title":"Cardiovasc Res"},{"key":"R24-20250802","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1161\/01.CIR.63.3.645","article-title":"Relation of the renin-angiotensin-aldosterone system to clinical state in congestive heart failure","volume":"63","author":"Dzau","year":"1981","journal-title":"Circulation"},{"key":"R25-20250802","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1093\/eurjhf\/hft100","article-title":"Serum aldosterone is associated with mortality and re-hospitalization in patients with reduced ejection fraction hospitalized for acute heart failure: analysis from the EVEREST trial","volume":"15","author":"Girerd","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"R26-20250802","doi-asserted-by":"crossref","first-page":"406","DOI":"10.5455\/medarh.2018.72.406-409","article-title":"Serum aldosterone as predictor of progression of coronary heart disease in patients without signs of heart failure after acute myocardial infarction","volume":"72","author":"Resic","year":"2018","journal-title":"Med Arch"},{"key":"R27-20250802","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1016\/S0735-1097(02)02382-3","article-title":"Beneficial neurohormonal profile of spironolactone in severe congestive heart failure: results from the RALES neurohormonal substudy [published correction appears in J Am Coll Cardiol. 2003 Nov 19;42(10):1865]","volume":"40","author":"Rousseau","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"R28-20250802","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/S0002-9149(99)80353-1","article-title":"Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease","volume":"76","author":"Barr","year":"1995","journal-title":"Am J Cardiol"},{"key":"R29-20250802","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1161\/01.CIR.82.5.1730","article-title":"Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group","volume":"82","author":"Swedberg","year":"1990","journal-title":"Circulation"},{"key":"R30-20250802","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"R31-20250802","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.cardfail.2017.04.014","article-title":"2017 ACC\/AHA\/HFSA Focused Update of the 2013 ACCF\/AHA Guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America","volume":"23","author":"Yancy","year":"2017","journal-title":"J Card Fail"},{"key":"R32-20250802","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"},{"key":"R33-20250802","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1161\/HYPERTENSIONAHA.115.06526","article-title":"Role of adding spironolactone and renal denervation in true resistant hypertension: one-year outcomes of randomized PRAGUE-15 study","volume":"67","author":"Rosa","year":"2016","journal-title":"Hypertension"},{"key":"R34-20250802","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","article-title":"Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial","volume":"386","author":"Williams","year":"2015","journal-title":"Lancet"},{"key":"R35-20250802","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1161\/01.HYP.0000259805.18468.8c","article-title":"Effect of spironolactone on blood pressure in subjects with resistant hypertension","volume":"49","author":"Chapman","year":"2007","journal-title":"Hypertension"},{"key":"R36-20250802","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1161\/HYPERTENSIONAHA.111.169961","article-title":"Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial","volume":"57","author":"V\u00e1clav\u00edk","year":"2011","journal-title":"Hypertension"},{"key":"R37-20250802","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1111\/j.1523-1755.2004.00913.x","article-title":"Spironolactone prevents early renal injury in streptozotocin-induced diabetic rats","volume":"66","author":"Fujisawa","year":"2004","journal-title":"Kidney Int"},{"key":"R38-20250802","doi-asserted-by":"crossref","first-page":"5363","DOI":"10.1210\/en.2006-0944","article-title":"Mineralocorticoid receptor antagonist reduces renal injury in rodent models of types 1 and 2 diabetes mellitus","volume":"147","author":"Guo","year":"2006","journal-title":"Endocrinology"},{"key":"R39-20250802","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1161\/01.HYP.31.1.451","article-title":"Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats","volume":"31","author":"Rocha","year":"1998","journal-title":"Hypertension"},{"key":"R40-20250802","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1046\/j.1523-1755.2003.00929.x","article-title":"Aldosterone\/salt induces renal inflammation and fibrosis in hypertensive rats","volume":"63","author":"Blasi","year":"2003","journal-title":"Kidney Int"},{"key":"R41-20250802","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1159\/000355736","article-title":"Eplerenone-mediated aldosterone blockade prevents renal fibrosis by reducing renal inflammation, interstitial cell proliferation and oxidative stress","volume":"37","author":"Chen","year":"2013","journal-title":"Kidney Blood Press Res"},{"key":"R42-20250802","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3390\/jcm7110459","article-title":"Long-term effects of spironolactone on kidney function and hyperkalemia-associated hospitalization in patients with chronic kidney disease","volume":"7","author":"Yang","year":"2018","journal-title":"J Clin Med"},{"key":"R43-20250802","first-page":"CD007004","article-title":"Aldosterone antagonists for preventing the progression of chronic kidney disease","volume":"4","author":"Bolignano","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"R44-20250802","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/S2213-8587(14)70194-9","article-title":"Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial [published correction appears in Lancet Diabetes Endocrinol. 2015 Apr;3(4):e3]","volume":"2","author":"Ando","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R45-20250802","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1111\/dme.13669","article-title":"Characteristics of high- and low-risk individuals in the PRIORITY study: urinary proteomics and mineralocorticoid receptor antagonism for prevention of diabetic nephropathy in Type 2 diabetes","volume":"35","author":"Tofte","year":"2018","journal-title":"Diabet Med"},{"key":"R46-20250802","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jacc.2018.04.070","article-title":"Medical therapy for heart failure with reduced ejection fraction","volume":"72","author":"Greene","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"R47-20250802","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1001\/jama.2009.1493","article-title":"Use of aldosterone antagonists in heart failure","volume":"302","author":"Albert","year":"2009","journal-title":"JAMA"},{"key":"R48-20250802","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s40620-019-00600-7","article-title":"New mineralocorticoid receptor antagonists: update on their use in chronic kidney disease and heart failure","volume":"33","author":"Capelli","year":"2020","journal-title":"J Nephrol"},{"key":"R49-20250802","first-page":"155","article-title":"Exploring the role of aldosterone in right ventricular function","volume":"30","author":"Harrison","year":"2014","journal-title":"Can J Cardiol"},{"key":"R56-20250802","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3389\/fphar.2013.00115","article-title":"PF-03882845, a non-steroidal mineralocorticoid receptor antagonist, prevents renal injury with reduced risk of hyperkalemia in an animal model of nephropathy","volume":"4","author":"Orena","year":"2013","journal-title":"Front Pharmacol"},{"key":"R57-20250802","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1093\/eurheartj\/ehw132","article-title":"A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and\/or chronic kidney disease","volume":"37","author":"Filippatos","year":"2016","journal-title":"Eur Heart J"},{"key":"R58-20250802","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jdiacomp.2016.11.021","article-title":"A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy","volume":"31","author":"Katayama","year":"2017","journal-title":"J Diabetes Complications"},{"key":"R59-20250802","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1253\/circj.CJ-16-0122","article-title":"A randomized controlled study of finerenone vs. eplerenone in Japanese patients with worsening chronic heart failure and diabetes and\/or chronic kidney disease","volume":"80","author":"Sato","year":"2016","journal-title":"Circ J"},{"key":"R60-20250802","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/jama.2015.10081","article-title":"Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"},{"key":"R61-20250802","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1038\/s41440-019-0211-0","article-title":"Effect of a novel nonsteroidal selective mineralocorticoid receptor antagonist, esaxerenone (CS-3150), on blood pressure and renal injury in high salt-treated type 2 diabetic mice","volume":"42","author":"Bhuiyan","year":"2019","journal-title":"Hypertens Res"},{"key":"R62-20250802","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1161\/HYPERTENSIONAHA.119.13569","article-title":"Double-blind randomized phase 3 study comparing esaxerenone (CS-3150) and eplerenone in patients with essential hypertension (ESAX-HTN Study)","volume":"75","author":"Ito","year":"2020","journal-title":"Hypertension"},{"key":"R63-20250802","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1038\/s41440-019-0314-7","article-title":"Long-term phase 3 study of esaxerenone as mono or combination therapy with other antihypertensive drugs in patients with essential hypertension","volume":"42","author":"Rakugi","year":"2019","journal-title":"Hypertens Res"},{"key":"R64-20250802","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","article-title":"Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial","volume":"34","author":"Pitt","year":"2013","journal-title":"Eur Heart J"},{"key":"R65-20250802","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1002\/jcph.865","article-title":"Population pharmacokinetics of LY2623091 in patients with hypertension and chronic kidney disease","volume":"57","author":"Wang","year":"2017","journal-title":"J Clin Pharmacol"},{"key":"R67-20250802","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.mce.2011.06.025","article-title":"Molecular pharmacology of the mineralocorticoid receptor: prospects for novel therapeutics","volume":"350","author":"Kolkhof","year":"2012","journal-title":"Mol Cell Endocrinol"},{"key":"R68-20250802","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1161\/01.HYP.0000193502.77417.17","article-title":"Mechanisms of mineralocorticoid action","volume":"46","author":"Fuller Peter","year":"2005","journal-title":"Hypertension"},{"key":"R69-20250802","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1530\/JOE-11-0372","article-title":"Mechanisms of ligand specificity of the mineralocorticoid receptor","volume":"213","author":"Fuller","year":"2012","journal-title":"J Endocrinol"},{"key":"R70-20250802","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/FJC.0000000000000091","article-title":"Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury","volume":"64","author":"Kolkhof","year":"2014","journal-title":"J Cardiovasc Pharmacol"},{"key":"R71-20250802","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/MNH.0000000000000147","article-title":"Nonsteroidal antagonists of the mineralocorticoid receptor","volume":"24","author":"Kolkhof","year":"2015","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"R73-20250802","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s13318-018-0483-9","article-title":"Pharmacokinetics of the novel, selective, non-steroidal mineralocorticoid receptor antagonist finerenone in healthy volunteers: results from an absolute bioavailability study and drug-drug interaction studies in vitro and in vivo","volume":"43","author":"Heinig","year":"2018","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"R74-20250802","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1124\/dmd.118.084897","article-title":"Pharmacokinetics, metabolism, and excretion of [14 C] esaxerenone, a novel mineralocorticoid receptor blocker in humans","volume":"47","author":"Yamada","year":"2019","journal-title":"Drug Metab Dispos"},{"key":"R75-20250802","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1124\/dmd.118.083337","article-title":"Biotransformation of finerenone, a novel nonsteroidal mineralocorticoid receptor antagonist, in dogs, rats, and humans, in vivo and in vitro","volume":"46","author":"Gerisch","year":"2018","journal-title":"Drug Metab Dispos"},{"key":"R76-20250802","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1002\/jps.2600650919","article-title":"Binding of spirolactones to human plasma proteins","volume":"65","author":"Chien","year":"1976","journal-title":"J Pharm Sci"},{"key":"R77-20250802","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s13318-019-00547-x","article-title":"Pharmacokinetics of the novel nonsteroidal mineralocorticoid receptor antagonist finerenone (BAY 94-8862) in individuals with mild or moderate hepatic impairment","volume":"44","author":"Heinig","year":"2019","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"R78-20250802","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s12325-019-01121-2","article-title":"Pharmacokinetics and safety of single-dose esaxerenone in Japanese subjects with mild to moderate hepatic impairment","volume":"37","author":"Kurata","year":"2020","journal-title":"Adv Ther"},{"key":"R79-20250802","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/BF00498838","article-title":"Pharmacokinetics of spironolactone in man","volume":"296","author":"Abshagen","year":"1976","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"R80-20250802","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1177\/0091270005275894","article-title":"Pharmacokinetics of eplerenone after single and multiple dosing in subjects with and without renal impairment","volume":"45","author":"Ravis","year":"2005","journal-title":"J Clin Pharmacol"},{"key":"R81-20250802","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/fcp.12170","article-title":"Pharmacokinetics, safety and tolerability of the novel, selective mineralocorticoid receptor antagonist finerenone\u2014results from first-in-man and relative bioavailability studies","volume":"30","author":"Lentini","year":"2016","journal-title":"Fundam Clin Pharmacol"},{"key":"R82-20250802","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1002\/cmdc.201200081","article-title":"Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases","volume":"7","author":"B\u00e4rfacker","year":"2012","journal-title":"ChemMedChem"},{"key":"R83-20250802","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0022-3565(25)22580-0","article-title":"Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro","volume":"240","author":"de Gasparo","year":"1987","journal-title":"J Pharmacol Exp Ther"},{"key":"R84-20250802","doi-asserted-by":"crossref","first-page":"T125","DOI":"10.1530\/JOE-16-0600","article-title":"30 years of the mineralocorticoid receptor: mineralocorticoid receptor antagonists: 60 years of research and development","volume":"234","author":"Kolkhof","year":"2017","journal-title":"J Endocrinol"},{"key":"R85-20250802","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/0022-4731(89)90169-6","article-title":"Antialdosterones: incidence and prevention of sexual side effects","volume":"32","author":"de Gasparo","year":"1989","journal-title":"J Steroid Biochem"},{"key":"R86-20250802","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0895-7061(02)02957-6","article-title":"Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension","volume":"15","author":"Weinberger","year":"2002","journal-title":"Am J Hypertens"},{"key":"R87-20250802","doi-asserted-by":"crossref","first-page":"21876","DOI":"10.1074\/jbc.M115.657957","article-title":"Finerenone impedes aldosterone-dependent nuclear import of the mineralocorticoid receptor and prevents genomic recruitment of steroid receptor coactivator-1","volume":"290","author":"Amazit","year":"2015","journal-title":"J Biol Chem"},{"key":"R88-20250802","doi-asserted-by":"crossref","first-page":"29932","DOI":"10.1074\/jbc.M110.131342","article-title":"A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule","volume":"285","author":"Fagart","year":"2010","journal-title":"J Biol Chem"},{"key":"R89-20250802","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/ejhf.444","article-title":"Non-steroidal mineralocorticoid receptor antagonism for the treatment of cardiovascular and renal disease: non-steroidal MR antagonism for treatment of cardiovascular and renal disease","volume":"18","author":"Bramlage","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"R90-20250802","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ejphar.2015.06.015","article-title":"Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist","volume":"761","author":"Arai","year":"2015","journal-title":"Eur J Pharmacol"},{"key":"R91-20250802","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jchf.2018.10.017","article-title":"Efficacy and safety of spironolactone in patients with HFpEF and chronic kidney disease","volume":"7","author":"Beldhuis","year":"2019","journal-title":"JACC Heart Fail"},{"key":"R92-20250802","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1016\/j.jacc.2012.07.048","article-title":"Influence of baseline and worsening renal function on efficacy of spironolactone in patients with severe heart failure","volume":"60","author":"Vardeny","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"R93-20250802","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.jchf.2019.09.011","article-title":"Mineralocorticoid receptor antagonists, blood pressure, and outcomes in heart failure with reduced ejection fraction","volume":"8","author":"Serenelli","year":"2020","journal-title":"JACC Heart Fail"},{"key":"R94-20250802","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1002\/ejhf.900","article-title":"Mineralocorticoid receptor antagonist pattern of use in heart failure with reduced ejection fraction: findings from BIOSTAT-CHF","volume":"19","author":"Ferreira","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"R95-20250802","doi-asserted-by":"crossref","first-page":"e0254","DOI":"10.1097\/MD.0000000000010254","article-title":"The use of a novel non-steroidal mineralocorticoid receptor antagonist finerenone for the treatment of chronic heart failure: a systematic review and meta-analysis","volume":"97","author":"Pei","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"R96-20250802","first-page":"157","article-title":"The predictive value of plasma biomarkers in discharged heart failure patients: role of plasma NT-proBNP","volume":"64","author":"Leto","year":"2016","journal-title":"Minerva Cardioangiol"},{"key":"R97-20250802","doi-asserted-by":"crossref","first-page":"180","DOI":"10.7326\/M16-1468","article-title":"Brain-type natriuretic peptide and amino-terminal pro-brain-type natriuretic peptide discharge thresholds for acute decompensated heart failure: a systematic review","volume":"166","author":"McQuade","year":"2017","journal-title":"Ann Intern Med"},{"key":"R99-20250802","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/s41371-019-0207-x","article-title":"Efficacy and safety of esaxerenone (CS-3150) for the treatment of essential hypertension: a phase 2 randomized, placebo-controlled, double-blind study","volume":"33","author":"Ito","year":"2019","journal-title":"J Hum Hypertens"},{"key":"R100-20250802","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1161\/CIRCULATIONAHA.118.033597","article-title":"Primary aldosteronism: a practical approach to diagnosis and management","volume":"138","author":"Byrd","year":"2018","journal-title":"Circulation"},{"key":"R101-20250802","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1016\/j.jacc.2007.07.067","article-title":"Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM Program","volume":"50","author":"Desai","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"R102-20250802","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/j.1365-2710.2005.00638.x","article-title":"Clinical factors associated with hyperkalemia in patients with congestive heart failure","volume":"30","author":"Ramadan","year":"2005","journal-title":"J Clin Pharm Ther"},{"key":"R103-20250802","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s00125-010-1922-6","article-title":"Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial","volume":"54","author":"Miao","year":"2011","journal-title":"Diabetologia"},{"key":"R104-20250802","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1159\/000503713","article-title":"Design and baseline characteristics of the finerenone in reducing kidney failure and disease progression in diabetic kidney disease trial","volume":"50","author":"Bakris","year":"2019","journal-title":"Am J Nephrol"},{"key":"R105-20250802","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1053\/j.ajkd.2019.06.009","article-title":"Change in albuminuria and gfr as end points for clinical trials in early stages of CKD: a scientific workshop sponsored by the national kidney foundation in collaboration with the US Food and drug administration and European medicines agency","volume":"75","author":"Levey","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"R106-20250802","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.2215\/CJN.14751218","article-title":"Efficacy and safety of esaxerenone (CS-3150) for the treatment of type 2 diabetes with microalbuminuria: a randomized, double-blind, placebo-controlled, phase II trial","volume":"14","author":"Ito","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"R107-20250802","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.2215\/CJN.06870520","article-title":"Esaxerenone (CS-3150) in patients with type 2 diabetes and microalbuminuria (ESAX-DN): phase 3 randomized controlled clinical trial","volume":"15","author":"Ito","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"R108-20250802","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Eng J Med"},{"key":"R109-20250802","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1056\/NEJMoa1616011","article-title":"Liraglutide and renal outcomes in type 2 diabetes","volume":"377","author":"Mann","year":"2017","journal-title":"N Engl J Med"},{"key":"R110-20250802","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Eng J Med"},{"key":"R111-20250802","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"R112-20250802","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"R113-20250802","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"R114-20250802","first-page":"S151","article-title":"11. Microvascular complications and foot care: standards of medical care in diabetes-2021","volume":"44","year":"2021","journal-title":"Diabetes Care"},{"key":"R115-20250802","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1159\/000503712","article-title":"Design and baseline characteristics of the finerenone in reducing cardiovascular mortality and morbidity in diabetic kidney disease trial","volume":"50","author":"Ruilope","year":"2019","journal-title":"Am J Nephrol"},{"key":"R117-20250802","doi-asserted-by":"crossref","first-page":"e578","DOI":"10.1161\/CIR.0000000000000560","article-title":"Evaluation and management of right-sided heart failure: a Scientific Statement rrom the American Heart Association","volume":"137","author":"Konstam","year":"2018","journal-title":"Circulation"},{"key":"R118-20250802","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/eurheartj\/ehv317","article-title":"2015 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS) Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT)","volume":"37","author":"Gali\u00e8","year":"2016","journal-title":"Eur Heart J"},{"key":"R119-20250802","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s10741-018-9758-0","article-title":"Effect of mineralocorticoid receptor antagonists on cardiac function in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis of randomized controlled trials","volume":"24","author":"Kapelios","year":"2019","journal-title":"Heart Fail Rev"},{"key":"R120-20250802","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1001\/jama.2013.905","article-title":"Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial","volume":"309","author":"Edelmann","year":"2013","journal-title":"JAMA"},{"key":"R121-20250802","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1161\/01.CIR.0000138680.89536.A9","article-title":"Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure","volume":"110","author":"Mottram","year":"2004","journal-title":"Circulation"},{"key":"R123-20250802","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1161\/HYPERTENSIONAHA.119.12676","article-title":"Emerging drug classes and their potential use in hypertension","volume":"74","author":"Azizi","year":"2019","journal-title":"Hypertension"}],"container-title":["Journal of Cardiovascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FJC.0000000000000990","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T22:06:29Z","timestamp":1754172389000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FJC.0000000000000990"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":111,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/fjc.0000000000000990","relation":{},"ISSN":["0160-2446"],"issn-type":[{"type":"print","value":"0160-2446"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"2020-06-01","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-01-28","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}